SI M024
Alternative Names: SI-M024Latest Information Update: 28 May 2023
At a glance
- Originator Sichuan Baili Pharmaceutical
- Developer Sichuan Baili Pharmaceutical; SystImmune
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2023 No recent reports of development identified for research development in Solid-tumours in China (Parenteral)
- 28 May 2023 No recent reports of development identified for research development in Solid-tumours in USA (Parenteral)
- 01 Apr 2019 Early research in Solid tumours in China and USA (Parenteral) before April 2019 (Sichuan Baili Pharmaceutical pipeline, April 2019)